• Estuary Biotherapeutics raised USD 93 million in Series A financing led by RA Capital Management, with participation from 4BIO Capital and GV.
• The financing brings total funding to USD 103 million, including a USD 10 million seed round co-led by the two returning investors.
• Estuary develops locally delivered gene therapies targeting the underlying genetic cause of autosomal dominant polycystic kidney disease.
• Proceeds will advance two lead programs through clinical proof of concept and support development of its kidney-targeting platform.
• EST-201, targeting patients with PKD2 mutations, is expected to enter clinical trials in 2027; EST-101, targeting PKD1 mutations, is expected in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BIO Partners LLP published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.